LearnDrugs.com
Nervous

CNS Stimulants (ADHD)

High-yield Verified · Jul 2026

Prototype: methylphenidate

Methylphenidate and amphetamines — controlled stimulants that, paradoxically, help focus in ADHD.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 The ADHD paradox — stimulants that calm

In ADHD, under-active dopamine and norepinephrine signaling in the brain’s frontal "executive" circuits impairs attention and impulse control. Stimulants increase dopamine and norepinephrine (methylphenidate blocks their reuptake; amphetamines also push more out) — which strengthens those focus circuits. The paradox is that a "stimulant" *calms* an ADHD patient, improving attention and reducing hyperactivity. They also treat narcolepsy by promoting wakefulness.

Boosting dopamine/norepinephrine strengthens frontal focus circuits — improving ADHD symptoms.

02 Controlled substances — abuse, the heart, and growth

Because they raise dopamine, stimulants have real abuse and dependence potential and are Schedule II controlled substances with a boxed warning — a central safety and legal consideration (secure storage, no early refills). They are sympathomimetic, so they raise heart rate and blood pressure; sudden cardiac events have occurred, so they are avoided in structural heart disease/serious arrhythmia, and cardiac history is screened before starting.

In children, two effects need monitoring: appetite suppression with slowed growth (track height/weight; "drug holidays" are sometimes used) and insomnia (dose earlier in the day). Amphetamines can also worsen tics, anxiety, and psychosis.

The three monitoring themes: abuse potential, cardiovascular effects, and growth/appetite/sleep.

Drug names

Generic Brand
methylphenidate Ritalin, Concerta
amphetamine/dextroamphetamine Adderall
lisdexamfetamine Vyvanse

Indications

  • Attention-deficit/hyperactivity disorder (ADHD)
  • Narcolepsy
  • Binge-eating disorder (lisdexamfetamine)

Mechanism of action

Increase synaptic dopamine and norepinephrine — methylphenidate blocks their reuptake; amphetamines block reuptake and promote presynaptic release. Enhanced catecholamine signaling in prefrontal circuits improves attention and impulse control.

In plain terms
They raise the brain’s dopamine and norepinephrine, which — in ADHD — improves focus and self-control.

Therapeutic effects — what you'll see working

Success is better attention/behavior (ADHD) or wakefulness (narcolepsy) with tolerable appetite, sleep, and cardiovascular effects. Effects are rapid; monitor growth over months.

Improved attention & reduced impulsivity Wakefulness
Improved attention & reduced impulsivity
Strengthened frontal catecholamine signaling improves focus and self-regulation in ADHD, often within the first doses.
Wakefulness
Promotes alertness in narcolepsy.

Adverse effects

The adverse effects are sympathetic overdrive (cardiovascular, appetite, sleep) plus the controlled-substance risks of abuse and psychiatric activation.

Caution: Common
Decreased appetite/weight loss, insomnia, headache, irritability, increased heart rate & blood pressure, dry mouth.
Appetite suppression and insomnia are the most common issues in children — dose in the morning and monitor growth.
Warning: Serious Hold & notify
Sudden cardiac events in structural heart disease; growth suppression (children); new/worsening psychosis, mania, tics; priapism; seizure lowering.
Screen for cardiac disease before starting; monitor height/weight in children. Stimulants can precipitate psychosis/mania and worsen tics.
Black-box warning — most severe: ■ Boxed warning · abuse & dependence
High potential for misuse, abuse, addiction, overdose, and death (Schedule II).
Assess for misuse/diversion, secure the medication, and avoid early refills. The FDA strengthened stimulant warnings to emphasize safe storage and use.

Interactions

MAOIs (or within 14 days) drug
Additive catecholamine release → hypertensive crisis — contraindicated.

Contraindications

The contraindications are the cardiac, psychiatric, and interaction states where sympathetic stimulation is dangerous.

Structural cardiac abnormality / serious arrhythmia / advanced atherosclerosis
Sympathomimetic effects can precipitate sudden cardiac events.
Concurrent MAOIs (or within 14 days)
Risk of hypertensive crisis from additive catecholamine effects.
History of substance use disorder; severe anxiety/agitation; hyperthyroidism, glaucoma use caution
High abuse potential and sympathetic stimulation worsen these conditions.

When to hold

Assess before giving — these findings mean hold the dose and act.

Elevated heart rate or blood pressure; chest pain, syncope, or other cardiac symptoms
Monitor HR/BP at baseline and periodically; hold and notify for significant elevation or cardiac symptoms.
Children — slowed growth or appetite suppression
Track height, weight, and appetite; report faltering growth (drug holidays may be considered).

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Monitoring
Screen cardiac history and monitor heart rate/blood pressure; monitor height and weight in children.
Why: Stimulants raise HR/BP (rare sudden cardiac events) and suppress appetite/growth.
Give the last dose early in the day; assess for misuse, mood changes, tics.
Why: Late doses cause insomnia; Schedule II drugs carry abuse and psychiatric-activation risk.
Patient/family teaching
Secure the medication, don’t share, and don’t stop abruptly after long high-dose use.
Why: These are controlled substances with abuse/diversion risk; abrupt withdrawal causes fatigue/depression.

Sources

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.